Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
With $30M, Oorja Bio breathes new life into fibrosis candidate
The biotech’s lead asset is ORJ-001, an activator of a receptor called β1 integrin that is key for maintaining lung structure and stability.
Darren Incorvaia
May 20, 2026 10:31am
Avalyn aims for $182M IPO to fund ph. 3 trials of lung drugs
Apr 24, 2026 7:08am
Avalyn plans IPO to fund ph. 3 trials of inhaled lung drugs
Apr 9, 2026 4:13am
Roche drops $100M Kiniksa fibrosis drug from ph. 2 pipeline
Jan 29, 2026 6:29am
GRI touts IPF safety edge, lung function gains amid cash crunch
Dec 11, 2025 5:12am
Tvardi's STAT3 inhibitor flunks IPF trial amid high dropout rate
Oct 13, 2025 9:25am
